Acadia Pharmaceuticals (NasdaqGS:ACAD) plans to present new remlifanserin clinical data at the 2026 CTAD Conference focused on Alzheimer's disease psychosis. The company is expected to share updated ...
Source LinkAcadia Pharmaceuticals (NasdaqGS:ACAD) plans to present new remlifanserin clinical data at the 2026 CTAD Conference focused on Alzheimer's disease psychosis. The company is expected to share updated ...
Source Link
Comments